


|

The Pathology of Prostate Cancer: From Population Studies to the Molecule
Moderators: Dr. John R. Srigley and Dr. Rodolfo Montironi
|
Section 7 -
|
Handling and Reporting Radical Prostatectomy Specimens

Lars Egevad, MD PhD
International Agency for Research on Cancer (IARC)
Lyon, France
|


The purposes of the histopathological examination of radical prostatectomy specimens are to verify the
preoperative diagnosis of cancer and to obtain information of prognostic importance, such as tumor type,
grade, stage and margin status [1]. In academic institutions, there is also a need to sample tissue for
research. Handling of these specimens was discussed by the pathology group at the WHO-sponsored
International Consultation on Prediction of Patient Outcome in Prostate Cancer in Stockholm 2004 and the
proceedings may serve as a guideline [2]. Recommendations have also been issued by The College of
American Pathologists
[3,
4].
Gross Examination and Handling of the Specimen

General considerations
There are a number of key issues that have to be addressed when deciding the local routine for
handling prostatectomy specimens.
 Should the prostatectomy specimen be submitted to the laboratory in formalin or unfixed?
For sampling of fresh tissue for research purposes, it is evidently necessary that the prostate is
transported unfixed. In institutions with no such research activity, it might be more convenient to send
the prostate to the pathology department in formalin. It is then important that the specimen is immersed
in a large quantity of formalin (at least 500 ml). In these cases, fixation can be improved by injecting
formalin into the prostate in the operation room (see below) [5].
 Should the prostate be totally embedded?
A problem when handling radical prostatectomy specimens is that cancer is often not visible at gross
examination and the tumor extent is always underestimated by the naked eye. For the pathologist, the
safest method to avoid under-sampling of cancer is to submit the entire prostate. However, this is
time-consuming for the laboratory and in many institutions, partial sampling is practiced. This requires
that the pathologist adheres to a strict protocol
[3,
4,
6].
 Should the prostate be wholemounted or should the slices be cut in smaller blocks to fit into standard cassettes?
There are pros and cons with both methods. Disadvantages with wholemount sections include that recuts
are more difficult to make and it is more expensive and difficult to perform immunohistochemistry.
Tissue microarrays can be constructed from wholemounts for immunohistochemistry but this technique
damages the paraffin blocks and it is a rather time-consuming process to set up a tissue microarray
experiment on prostate cancer. Moreover, wholemount sections do not fit into standard slide holders for
slide collections and standard slide archives. Yet, wholemount sections give the pathologist a better
overview and the identification of multiple separate tumor foci is facilitated. Lab technicians who are
used to cut wholemounts usually find them less time-consuming than cutting multiple small blocks.

Handling of unfixed prostatectomy specimens
The fluid secreted by the prostate gland is known to contain abundant proteolytic enzymes causing
rapid proteolytic degradation. Hence, the prostate should be immersed in ice immediately after surgery
and rapidly transported to the pathology department. Formalin fixation should be performed as soon as
possible after harvesting of research samples (see below).

Sampling for research purposes
Several techniques have been described for harvesting of fresh tissue. Samples can be punched by core
needle or punch biopsies
[5,
7,
8]
but the tissue yield with this method is small. It is also difficult
to localize cancer when biopsies are taken from the outside of the prostate gland. If the prostate is
incised (e.g. cut in half by a horizontal section), the cut surfaces can be inspected and sampled where
tumor is seen grossly [9]. To prevent deformation of the prostate during fixation, the prostatic capsule
is pinned out and wholemount sections can still be obtained. If the unfixed prostate is cut into
multiple small blocks for submission in standard cassettes, sampling can easily be done from any grossly
visible cancer.

Formalin fixation
Formalin injection into the specimen before immersion in formalin improves fixation [5]. In a study
from our group (unpublished data), there was no difference in tissue shrinkage between specimens injected
with 20 ml formalin and prostates that underwent conventional fixation. Hence, the same volume
correction factor may be used for planimetrical tumor volume measurements. No needle tracks or other
traces of the injection (such as edema) are seen in the histological sections. The prostate is then
immersed in formalin in a large jar. Fixation can be enhanced by circulating the formalin with an
aquarium pump.

After fixation the prostate should be inked. There are several commercially available ink systems.
It is recommended that several different colors (at least 3) are used in order to facilitate orientation.
The adhesion of the ink can be improved by dipping the prostate in 5% acetic acid.

The apex
The apical margin is a common location for positive margins and should be examined carefully. The
shave technique is no longer recommended [2]. A better method is to amputate a thick section from the
apex and then cut it sagittally.

The base
Positive surgical margins are less often seen in the base area than at the apex. Therefore, the base
may either be examined by sagittal sections as described for the apex, or a thin shave slice may be
removed and embedded en face. [2]

Slicing of the prostate
After the apical slice has been removed, the prostate is sliced at 3 - 4 mm. An electric meat cutter
is helpful when slicing the formalin fixed prostate. However, there is a risk that the cutter removes
the surgical margin at the end of the slice. This can be avoided if the last part of each slice is cut
by hand.

The seminal vesicles
The seminal vesicles and vasa deferentia may be cut longitudinally and both halves embedded. However,
seminal vesicle invasion is nowadays relatively rarely seen and complete embedment of these structures is
not mandatory. As seminal vesicles are usually invaded through their attachment to the prostate, a
minimum requirement is that a section through the base of the seminal vesicle is submitted.
Gross features of Prostate Cancer
Prostate cancer is often difficult to see grossly and this is particularly true for small tumors.
When cancer can be identified at gross examination, it is typically very poorly circumscribed. The color
of the tumors ranges from bright yellow to pale tan. Sometimes the tumor is merely firmer than normal
prostatic tissue but has normal color. Transition zone cancers are especially difficult to see [6].
They typically grow within hyperplastic nodules and the nodularity of pre-existing hyperplasia is
preserved. The only sign of cancer may be that a transition zone nodule is slightly more yellow than
normal. The microscopic extension of prostate cancer is almost always greater than expected from the
gross features.
 Reporting of Radical Prostatectomy Specimens

Extra-prostatic extension
The prostatic capsule is a poorly defined structure and not a true capsule. The prostatic "capsule"
refers to the transition between relatively condensed prostatic stroma and more loosely arranged
extra-prostatic connective tissue. Hence, extra-prostatic extension is a better terminology than capsule
penetration. Extra-prostatic extension is most common in the dorsolateral region at the neurovascular
bundle. In most cases of extra-prostatic extension, there is tumor growth in adipose tissue. However,
as opposed to core biopsies, prostatectomy specimens may be diagnosed with extra-prostatic extension even
when extra-prostatic cancer is surrounded by desmoplastic connective tissue. The capsule is particularly
poorly defined around the apex, anteriorly and at the bladder neck, and in these areas, growth in or at
the level of adipose tissue is required for a diagnosis of extra-prostatic extension. At the apex and
anteriorly, there is a continuous transition between prostatic tissue and striated muscle tissue of the
pelvic floor. Hence, growth around striated muscle does not necessarily indicate extra-prostatic
extension.

Extra-prostatic extension can be stratified as focal vs. established (or extensive or non-focal)
[10,
11].
Patients with focal extra-prostatic extension have a more favorable outcome after radical
prostatectomy. However, there is no uniform definition of these categories: measures such as "a few
glands outside the prostate" [11] or
"less than one high-power field" [10] have been used to define focal
extra-prostatic extension.

Surgical margins
The prostatectomy specimen is only surrounded by a thin layer of connective tissue and a wide surgical
margin cannot be expected. For a margin to be considered positive, cancer has to reach ink. A margin is
reported as negative if cancer is separated from ink by as little as a few collagen fibres. Positive
margins are most common at the apex but may occur anywhere.

Seminal vesicle invasion
Cancer invading the seminal vesicle conveys a poor prognosis. Cancer usually invades by direct
overgrowth from the basal parts of the prostate. Three anatomical patterns of seminal vesicle invasion
have been described [12] but the prognostic value of these categories has not been confirmed by others
[13].

Zonal origin and distribution
It has been suggested that transition zone (TZ) tumors have a better prognosis than peripheral zone
(PZ) tumors of the same grade and size, possibly because of the greater distance to the capsule. Hence,
the zonal origin of prostate cancer should be reported in prostatectomy specimens. When the tumor is
large and extends into both the PZ and the TZ, it may be impossible to determine its origin.

Tumor volume
There are several methods for estimation of tumor volume, including planimetry, the grid method, the
percentage of the specimen involved by cancer and maximum tumor diameter. Volume of prostate cancer
correlates with other prognostic factors such as grade, stage and ploidy and also with prognosis after
radical prostatectomy. Some authors have reported that tumor volume is not an independent predictor of
prognosis when Gleason score, extra-prostatic extension, surgical margins and seminal vesicle invasion
are included in the analysis
[14,
15].
This may be true when the majority of tumors are small. Other
studies based on series with larger tumors have found that tumor volume is an independent prognostic
factor [16]. Because of these conflicting data, measurement and reporting of tumor volume is not
mandatory.
Grading of Prostate Cancer in Radical Prostatectomy Specimens
The histopathological tumor grade is the most important tissue-based prognostic factor of prostate
cancer. The Gleason grading system is now uniformly used for grading of prostate cancer and has been
adopted by the WHO [17]. Detailed descriptions of this grading are given on several web resources such
as:

http://pathology2.jhu.edu/gleason/

http://www.pathology.ks.se/egevad/gleason.html

The Gleason patterns
Gleason scores 2 and 3 are only exceptionally assigned, because Gleason pattern 1 is unusual. Gleason
score 4 is also relatively uncommon because pattern 2 is usually mixed with some pattern 3 resulting in a
Gleason score 5. Normal prostate epithelial cells are arranged around a lumen. In patterns 1 to 3, there
is retained epithelial polarity with luminal differentiation in virtually all glands. In pattern 4,
there is partial loss of normal polarity and in pattern 5, there is an almost total loss of polarity with
only occasional luminal differentiation.

The 2005 ISUP Consensus Conference on Gleason Grading of Prostatic Carcinoma
At an ISUP (International Society of Urological Pathology) consensus conference in 2005, the Gleason
grading system for prostatic carcinoma underwent its first major revision including both pattern
interpretation and compiling and reporting of grade information [18]. The most important modifications
of pattern interpretation proposed by the ISUP meeting pertained to patterns 3 and 4. In the original
description by Gleason, cribriform patterns were assigned either a Gleason pattern 3 or 4 depending on
the shape of the cribriform glands. There is now an increased understanding that invasive cribriform
carcinoma is a relatively aggressive disease. Therefore, it was now recommended that most cribriform
carcinomas should be assigned a Gleason pattern 4 rather than 3 and that cribriform glands must be small
and round to qualify for pattern 3. The ISUP consensus meeting emphasized that Gleason pattern 4 should
also include ill-defined glands with poorly formed glandular lumina, a relatively common pattern that was
not incorporated in the original definition of pattern 4.

Reporting of tertiary Gleason patterns
Gleason defined the Gleason score as the sum of primary (dominant) and secondary (next most common)
patterns. However, a recommendation was issued at the ISUP meeting that Gleason scores of needle
biopsies should include any amount of high-grade tumor, even if less than 5% of all cancer present [18].
This may be justified because grading of needle biopsies serves as a guideline for the clinician on how
to handle the patient rather than providing a definitive Gleason score. When reporting a radical
prostatectomy specimen, the enitre cancer is available for grading and there was a consensus that for
radical prostatectomy specimen, one assigns a Gleason score based on the primary and secondary patterns
with a comment when a tertiary pattern is present.

Grading of separate tumor foci
Prostate cancer is a strikingly multifocal disease. The recommendation of the ISUP consensus meeting
was that separate Gleason scores should be assigned when more than one major tumor focus is present. If
for example the dominant tumor focus is a Gleason score 4+4=8 peripheral zone cancer and there is a
separate Gleason score 2+2=4 transition zone cancer, the prognosis of the high-grade cancer is not
improved by the presence of the low-grade tumor. Hence, it would be misleading to assign a Gleason score
4+2=6.

Crush artefacts
Crush artefacts are particularly common at the margins of radical prostatectomy specimens. Crush
artefacts cause disruption of the glandular units and consequently may lead to overgrading of prostate
cancer. These artefacts are recognized by the presence of noncohesive epithelial cells with fragmented
cytoplasm and dark, pyknotic nuclei adjacent to preserved cells. Crushed areas should not be Gleason
graded.

Gleason score and prognosis
Multiple studies have confirmed that Gleason score is a very powerful prognostic factor, both for
prediction of the natural history of prostate cancer
[19,
20]
and for assessment of the risk of
recurrence after radical prostatectomy
[21,
22]
or radiotherapy [23]. The major increase of the
likelihood of having adverse findings in the prostatectomy specimen or with failure following
prostatectomy or radiotherapy is from Gleason score 6 to 7. Evidently, the appearance of Gleason pattern
4 cancer has a significantly negative effect on prognosis. The amount of high grade cancer (patterns 4
to 5) also correlates with tumor progression. Gleason score 7 cancers with a primary pattern 4 have more
advanced pathological stage and higher risk of disease progression after prostatectomy than those with a
primary pattern 3
[24,
25].
It has also been shown that percent of tumor occupied by Gleason patterns 4
or 5 predicts recurrence after prostatectomy as estimated by serum prostate specific antigen [26]. Yet,
percent Gleason grade 4/5 is unlikely to be utilized by a majority of pathologists.

References:
- Srigley, J. R., Arch Pathol Lab Med 2006, 130, 303–317.

- Epstein, J. I., Amin, M., Boccon-Gibod, L., Egevad, L., et al., Scand J Urol Nephrol Suppl 2005, 34-63.

- Srigley, J. R., Amin, M. B., Bostwick, D. G., Grignon, D. J. and Hammond, M. E., Arch Pathol Lab Med 2000, 124, 1034-1039.

- Srigley, J. R., Amin, M. B., Epstein, J. I., Grignon, D. J., et al., Arch Pathol Lab Med 2006:130, 936-946.

- Hoedemaeker, R. F., Ruijter, E. T. G., Ruizeveld-de Winter, J. A., van der Kaa, C. A. and van der Kwast, T. H., Journal of Urologic Pathology 1998, 9, 211-222.

- Hall, G. S., Kramer, C. E. and Epstein, J. I., Am J Surg Pathol 1992, 16, 315-324.

- Furman, J., Murphy, W. M., Rice, L., Drew, P. A. and Narayan, P., Am J Clin Pathol 1998, 110, 4-9.

- Wheeler, T. M. and Lebovitz, R. M., Prostate 1994, 25, 274-279.

- Egevad, L., Engström, K. and Busch, C., Journal of Urologic Pathology, in press 1998, 9, 17-28.

- Wheeler, T. M., Dillioglugil, O., Kattan, M. W., Arakawa, A., et al., Hum Pathol 1998, 29, 856-862.

- Epstein, J. I., Pizov, G. and Walsh, P. C., Cancer 1993, 71, 3582-3593.

- Ohori, M., Scardino, P. T., Lapin, S. L., Seale-Hawkins, C., et al., Am J Surg Pathol 1993, 17, 1252-1261.

- Epstein, J. I., Partin, A. W., Potter, S. R. and Walsh, P. C., Urology 2000, 56, 283-288.

- Epstein, J. I., Carmichael, M., Partin, A. W. and Walsh, P. C., J Urol 1993, 149, 1478-1481.

- Kikuchi, E., Scardino, P. T., Wheeler, T. M., Slawin, K. M. and Ohori, M., J Urol 2004, 172, 508-511.

- Humphrey, P. A., Walther, P. J., Currin, S. M. and Vollmer, R. T., Am J Surg Pathol 1991, 15, 1165-1170.

- Eble, J. N., Sauter, G., Epstein, J. I. and Sesterhenn, I. A., Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs, IARC Press, Lyon 2004.

- Epstein, J. I., Allsbrook, W. C., Jr., Amin, M. B. and Egevad, L., Am J Surg Pathol 2005, 29, 1228-1242.

- Albertsen, P. C., Fryback, D. G., Storer, B. E., Kolon, T. F. and Fine, J., JAMA 1995, 274, 626-631.

- Egevad, L., Granfors, T., Karlberg, L., Bergh, A. and Stattin, P., BJU Int 2002, 89, 538-542.

- Epstein, J. I., Partin, A. W., Sauvageot, J. and Walsh, P. C., Am J Surg Pathol 1996, 20, 286-292.

- Hull, G. W., Rabbani, F., Abbas, F., Wheeler, T. M., et al., J Urol 2002, 167, 528-534.

- Green, G. A., Hanlon, A. L., Al-Saleem, T. and Hanks, G. E., Cancer 1998, 83, 971-976.

- Chan, T. Y., Partin, A. W., Walsh, P. C. and Epstein, J. I., Urology 2000, 56, 823-827.

- Sakr, W. A., Tefilli, M. V., Grignon, D. J., Banerjee, M., et al., Urology 2000, 56, 730-734.

- Stamey, T. A., McNeal, J. E., Yemoto, C. M., Sigal, B. M. and Johnstone, I. M., JAMA 1999, 281, 1395-1400.
|


|
|
|